Table 2.

Correlation between insulin‐like growth factor receptor type 1 (IGF1R), epidermal growth factor receptor and human epidermal growth factor receptor type 2 overexpression with clinicopathological parameters and hormone receptor status in breast cancer

Parameter	Total	Cases
		IGF1R		EGFR		HER2
		n	%	n	%	n	%
Total	150	71	47	12	8	23	15
Hormone receptor status
ER+	77	48	62*	0	0 †	2	3 ‡
ER−	73	23	32	12	16	21	29
PgR+	87	54	62 §	1	1 ¶	6	7**
PgR−	63	17	27	11	17	17	27
Hormone receptor status combined
ER+/PgR+	63	42	67 ††	0	0 ‡‡	2	3 §§
ER+/PgR−	14	6	43	0	0	0	0
ER−/PgR+	24	12	50	1	4	4	17
ER−/PgR−	49	11	22	11	22	17	35
Histological grade
Invasive ductal carcinoma	130	58	45	11	8	18	14
Ductal carcinoma in situ	15	8	53	1	7	5	33
Invasive lobular carcinoma	5	3	60	0	0	0	0
Nuclear grade
Grade 1	17	12	71 ¶¶	0	0***	2	12
Grade 2	84	42	50	2	2	10	12
Grade 3	49	17	35	10	20	11	22
Age (years)
<50	57	21	37	6	11	9	16
≥50	93	50	54	6	6	14	15
Tumor size (cm)
<2.0	42	15	36	3	7	8	19
≥2.0	108	56	52	9	8	15	14
Lymph node status
Positive	52	23	44	6	12	7	13
Negative	77	33	43	4	5	14	18
Unknown	21	15	71	2	10	2	10

^* P = 0.0005,

^† P < 0.0001 and

^‡ P < 0.0001 between estrogen receptor (ER)‐positive and ER‐negative cases;

^§ P < 0.0001,

^¶ P < 0.0001 and

^** P = 0.0007 between progesterone receptor (PgR)‐positive and PgR‐negative cases;

^†† P = 0.002,

^‡‡ P < 0.0001 and

^§§ P = 0.003 between ER‐ and/or PgR‐positive cases and double‐negative ER and PgR cases;

^¶¶ P = 0.03,

^*** P = 0.026 between the grade 1, 2 and 3 cases.